Stream it or skip it: ‘David’ on Netflix, a beautifully animated reiteration of the classic Bible story

Angel Studios enjoyed a nice theatrical hit with this metaphorical rock slung at the noggins of bigger animation houses.
ophthalmologyadvisor

Complement Inhibitors Linked With AMD Progression, No Visual Function Improvement

ARVO presenters conducted a retrospective study to assess the visual and anatomical outcomes of patients receiving complement inhibitors for geographic atrophy. In a real-world cohort of patients with ...
IEEE

A Generalized Fuzzy Complement Function for Low-light Image Enhancement

Abstract: Classical fuzzy complement functions compute the non-membership grades of elements based solely on their membership values. However, they often fall short in effectively representing ...
The Hollywood Reporter

YouTube Report Details Animation Industry Indie Wave, Reveals Viewership Trends (Exclusive)

Maddy Buxton, Culture & Trends manager at YouTube, discusses how creators and digital animation on the platform are global, fan-driven, popular among young adults, and driving innovation and ...
Consumer Reports

Does the Start/Stop Function Really Improve Your Car’s Fuel Economy?

Recently, Environmental Protection Agency Administrator Lee Zeldin announced the end of federal credits for automakers that install start/stop systems, part of a broader overhaul of greenhouse gas ...
MedPage Today

FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No.

The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to ...
Business Wire

Omeros Announces First Commercial Sales of YARTEMLEA ®

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
FiercePharma

Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved

The FDA has approved Omeros' Yartemlea as the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. It is the first FDA nod for the 31-year-old Seattle biotech.
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
Nasdaq

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of ...
IndieWire

Every Walt Disney Animation Studio Film, Ranked

It feels churlish, in this day and age, to come on the internet and celebrate Disney. Less a movie studio and more a terrifying global monopoly, the Walt Disney Corporation has grown so worryingly ...